As expression of the TIGIT ligands, CD112 and CD155, has been shown in different cancers [10], including NB [11], the blockade of TIGIT presents a further attractive therapeutic strategy, especially in the context of Ab-based immunotherapies, and has been already reported in experimental models to promote an NK-cell-dependent antitumor response in vitro and in vivo [10]. Here, TIGIT is linked to cancer.